Bank of America Securities sticks to its Buy rating for Genmab (GMAB). Nov. 7, 2026, 12:35 AM Bank of America Securities analyst Charlie Haywood maintained a Buy rating on Genmab yesterday. The company's shares closed yesterday at $53.63. According to TipRanks, Haywood is ranked #1033 out of 12470 analysts. In addition to Bank of America Securities, Genmab also received a Buy from Truist Financial's Gregory Renza in a report issued yesterday. However, on the same day, Morgan Stanley maintained a Hold rating on Genmab (NASDAQ: GMAB). Based on Genmab's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.16 billion and a net profit of $303 million. In comparison, last year the company earned a revenue of $924.81 million and had a net profit of $335.93 million Read More on GMAB:

Genmab CFO backs analysts' 2027 cost estimates. Regulatory approvals are still pending, but Genmab is preparing to launch Rina-S for platinum-resistant ovarian cancer and petosemtamab for head and neck cancer. Marketwire 6 November 2026at 11:33 Genmab will keep a disciplined approach to costs in 2027, though the Danish biotech company will need to invest in research and development as well as new product launches. That was the message from Chief Financial Officer Anthony Pagano on a conference call Thursday, when he pointed to analysts' own forecasts for next year's costs. "I'd like to take a minute to look ahead to 2027. While, of course, our guidance will be given in February next year, as I stand here today, 2027 consensus expectations for opex on Bloomberg and FactSet appear to be in a reasonable place, capturing our investment priorities," Pagano said. According to AL Sydbank analyst Søren Løntoft Hansen, clarity on costs has been a theme in the stock market. In October, a series of promising clinical results put two potential new cancer drugs within Genmab's reach. Regulatory approvals are still pending, but Genmab is preparing to launch both Rina-S for platinum-resistant ovarian cancer and petosemtamab for head and neck cancer. According to Bloomberg, the 2027 consensus estimate for Genmab's operating expenses is about USD 3.3bn. Of that, USD 2.3bn is for research and development and USD 1bn for selling, general, and administrative expenses. If operating expenses land at that level, which Pagano says looks reasonable, it would mean an increase of about USD 400m compared with the midpoint of Genmab's 2026 guidance. Earnings should be able to absorb that. "Importantly, we remain confident that Genmab will deliver strong profitability both in 2026 and continued growth in 2027," Pagano said. Aiming above the midpoint of 2026 guidance. Pagano also offered more detail on Genmab's 2026 outlook. The company still expects revenue of USD 4,325m-4,525m, or USD 4,425m at the midpoint. "Given our performance through the first nine months, we now expect revenue to be in the upper part of that range," Pagano said. Operating expenses, on the other hand, will rise significantly in the fourth quarter. According to Pagano, they will therefore probably land at the midpoint of the 2026 guidance. "We expect Q4 opex to step up significantly because we have substantial activity planned in the fourth quarter, including manufacturing, clinical development, and launch readiness for Rina-S and petosemtamab. So I would caution against taking down your 2026 opex figures as a result of our first nine months." That also means operating profit is heading toward the upper end of Genmab's range. "With revenue in the upper part of the range and opex around the midpoint, we expect our operating profit to end above that midpoint," Pagano said. The midpoint of Genmab's operating profit guidance for this year is USD 1,225m, with a range of USD 1,065m to USD 1,385m. English edit by Daniel Frank Christensen